I greatly enjoyed reading The CJP's April 2011 articles on placebos, which provided food for thought on several related issues. I was especially intrigued by the Raz and colleagues 1 fi nding "that psychiatrists prescribed signifi cantly more subtherapeutic doses of medication than physicians in other specialties." p 198 Who decides what constitutes a subtherapeutic dose-doctor, patient, expert opinion, or pharmaceutical industry?
New research should cause us to re-evaluate our assumptions on dosing. I will not belabour the important contributions of concomitant medication, comorbidities, or tobacco or alcohol use on serum drug levels but focus instead on instructive results from a recent study on paroxetine plasma levels in 74 pregnant patients with depression. 2 The cytochrome P450 (CYP) 2D6 genotypes in this observational cohort study revealed 5 poor metabolizers (PMs), 25 intermediate metabolizers (IMs), 43 extensive metabolizers (EMs), and 1 ultrarapid metabolizer (UM). Women who were EMs and UMs for CYP 2D6 showed steadily decreasing plasma paroxetine concentrations during pregnancy, while IMs and PMs showed steadily increasing concentrations in each week of pregnancy. The reduced plasma paroxetine levels in EMs and UMs were shown to signifi cantly correlate with increased depressive symptoms during the course of pregnancy, while increased levels in IMs and PMs did not change depressive symptoms. However, it is possible that the 40% of IMs and PMs might have obtained therapeutic antidepressant effects from much lower subtherapeutic doses of paroxetine. Moreover, the effects on the fetus of the increasing plasma levels of paroxetine in the IMs and PMs are unknown and urgently need further study to see if they contribute to cardiac teratology, low birth weight, or poor neonatal adaptation. 
Multifactorial Aspects of Subtherapeutic Effectiveness
Dear Editor:
Thank you for the opportunity to respond to the letter submitted by Dr Stewart concerning the contentious meaning of a subtherapeutic dose. We recently explored at length the vagaries of subtherapeutic doses and their place in the armamentarium of the modern clinician. 1 We sketch below a brief overview of some of the issues that surround the response variability to antidepressants (ADs).
Multifactorial considerations-spanning the spectrum of psychosocial parameters, pharmacogenetic variables, all the way to market forces-complicate our ability to pinpoint the nature of responses to subtherapeutic doses of ADs. A subtherapeutic dose refers to a small amount of active biochemical material-too little to account for a clinical outcome. If a clinically viable outcome occurs at such a minimal dose, however, explanations drawing on metabolic and placebo mechanisms become equally plausible. Teasing apart the infl uence of psychosocial parameters from biochemical dose-response reifi es the precarious relation between low-dose medication and placebo. Investigating this relation further contextualizes the ongoing ADs-versus-placebos debate in the treatment of depression. 2 Pharmacogenetic assays examine changes that occur at the resolution of enzymes that metabolize ADs; uncertainty lingers, however, how and whether these phenomena wield clinical effects. Five to 10% of Caucasians have genetic polymorphisms in cytochrome P450 (CYP) 2D6 that render them poor metabolizers of most ADs. 3 Findings have yet to substantiate, however, a clear infl uence of the most frequent CYP 2D6 polymorphisms on depression outcome. 4 A distinct circumstance of altered drug metabolism, pregnancy provides evidence of clinical effects but only in terms of increased depression symptoms among extensive or ultrarapid metabolizers. Using genetic screening to optimize treatment outcomes remains elusive, especially because administrating ADs typically starts low with upward dose titrations dependant on patient response. 4
Regulatory agencies, the pharmaceutical industry, and the associated market forces constitute a major component in the dosing of medications. One controversial theme proposes that ADs are clinically effective at doses considerably lower than those recommended in the product monographs. Re-examination of early studies of fl uoxetine, for example, supports the idea of starting
